Market Access/ News/ News NICE restores parity between Alnylam and Akcea on rare disease Phil Taylor Alnylam, hATTR, NICE, rare disease 0 Comment NICE has reversed its stance on Alnylam’s gene-silencing drug Onpattro for rare disease hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), Share X NICE restores parity between Alnylam and Akcea on rare disease https://pharmaphorum.com/news/nice-restores-parity-between-alnylam-and-akcea-on-rare-disease/
Market Access/ News/ News NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okay Phil Taylor Akcea, Alnylam, hATTR, market access, NICE, Rare diseases 0 Comment NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in Share X NICE backs Akcea’s Tegsedi, pipping Alnylam to hATTR okay https://pharmaphorum.com/news/nice-backs-akceas-tegsedi-pipping-alnylam-to-hattr-okay/
